Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

3(60.0%)

Phase 4

2(40.0%)

5Total

N/A(3)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT00992420Completed

Genotype Information and Functional Testing Study

Role: collaborator

NCT01538446Phase 4Completed

Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel

Role: collaborator

NCT01582217Completed

Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition

Role: collaborator

NCT01276678Unknown

Multi-Analyte, Genetic, and Thrombogenic Markers of Atherosclerosis

Role: collaborator

NCT00766896Phase 4Completed

Platelet Hyperreactivity to Aspirin and Stroke

Role: collaborator

NCT01257893Not ApplicableWithdrawn

Aspirin Resistance in Women With Migraine

Role: collaborator

NCT01534117Not ApplicableCompleted

Platelet Function Analysis in Head Trauma: ASA/Plavix

Role: collaborator

NCT00645918Not ApplicableCompleted

GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety

Role: lead

All 8 trials loaded